JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling

Overactive Janus kinases (JAKs) are known to drive leukemia, making them well-suited targets for treatment. We sought to identify new JAK-activating mutations and instead found a JAK1-inactivating pseudokinase mutation, V666G. In contrast to other pseudokinase mutations that canonically lead to an active kinase, the JAK1 V666G mutation led to under-activation seen by reduced phosphorylation. To understand the functional role of JAK1 V666G in modifying kinase activity we investigated its influence on other JAK kinases and within the Interleukin-2 pathway. JAK1 V666G not only inhibited its own activity, but its presence could inhibit other JAK kinases. These findings provide new insights into the potential of JAK1 pseudokinase to modulate its own activity, as well as of other JAK kinases. Thus, the features of the JAK1 V666 region in modifying JAK kinases can be exploited to allosterically inhibit overactive JAKs.

[1]  R. Roskoski.  Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders. , 2022, Pharmacological research.

[2]  P. Lupardus,et al.  Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation , 2022, Science.

[3]  Subhashish Banerjee,et al.  Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors , 2021, Dermatology and Therapy.

[4]  Alice H. Grant,et al.  The Genomic Landscape of a Restricted ALL Cohort from Patients Residing on the U.S./Mexico Border , 2021, International journal of environmental research and public health.

[5]  R. Roskoski.  Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update. , 2021, Pharmacological research.

[6]  S. Cohen.  JAK inhibitors and VTE risk: how concerned should we be? , 2021, Nature Reviews Rheumatology.

[7]  O. Silvennoinen,et al.  Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling , 2019, Cancers.

[8]  S. Spergel,et al.  Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. , 2019, Journal of medicinal chemistry.

[9]  O. Silvennoinen,et al.  The regulation of JAKs in cytokine signaling and its breakdown in disease. , 2019, Cytokine.

[10]  K. Nakai,et al.  Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor. , 2018, Bioorganic & medicinal chemistry.

[11]  Marilyn M. Li,et al.  Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure , 2018, Haematologica.

[12]  S. Yao,et al.  The molecular basis of JAK/STAT inhibition by SOCS1 , 2018, Nature Communications.

[13]  J. Soulier,et al.  Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL. , 2018, Blood.

[14]  W. Vainchenker,et al.  JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders , 2018, F1000Research.

[15]  P. Stephens,et al.  Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion , 2017, PloS one.

[16]  M. Loh,et al.  Philadelphia chromosome-like acute lymphoblastic leukemia. , 2017, Blood.

[17]  M. Loh,et al.  Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL. , 2017, Blood advances.

[18]  Jens Meiler,et al.  Quantitative Structure–Activity Relationship Modeling of Kinase Selectivity Profiles , 2017, Molecules.

[19]  Ka-Chun Wong,et al.  Big Data Analytics in Genomics , 2016, Springer International Publishing.

[20]  R. Kirken,et al.  Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors. , 2016, Clinical cancer drugs.

[21]  R. Roskoski.  Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. , 2016, Pharmacological research.

[22]  J. Meijerink,et al.  Structural modeling of JAK1 mutations in T-cell acute lymphoblastic leukemia reveals a second contact site between pseudokinase and kinase domains , 2016, Haematologica.

[23]  O. Silvennoinen,et al.  Nucleotide-binding mechanisms in pseudokinases , 2015, Bioscience reports.

[24]  M. Loh,et al.  A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011) , 2015, Pediatric blood & cancer.

[25]  J. Soulier,et al.  Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia , 2015, Haematologica.

[26]  C. Gabel,et al.  Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2)* , 2015, The Journal of Biological Chemistry.

[27]  Yongwook Choi,et al.  PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels , 2015, Bioinform..

[28]  E. Estey,et al.  Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia , 2015, Pediatric blood & cancer.

[29]  Doriano Fabbro,et al.  Ten things you should know about protein kinases: IUPHAR Review 14 , 2015, British journal of pharmacology.

[30]  S. Hubbard,et al.  ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation , 2015, Proceedings of the National Academy of Sciences.

[31]  S. Aerts,et al.  JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. , 2014, Blood.

[32]  T. Rausch,et al.  The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse , 2014, Haematologica.

[33]  N. Nicola,et al.  The molecular regulation of Janus kinase (JAK) activation. , 2014, The Biochemical journal.

[34]  Adam R. Johnson,et al.  Structure of the pseudokinase–kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition , 2014, Proceedings of the National Academy of Sciences.

[35]  Guillermo A. Gomez,et al.  Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor , 2014, Science.

[36]  O. Silvennoinen,et al.  Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses. , 2014, The Biochemical journal.

[37]  Chae Un Kim,et al.  Structure of a pseudokinase domain switch that controls oncogenic activation of Jak kinases , 2013, Nature Structural &Molecular Biology.

[38]  Ethan A Merritt,et al.  Sequence determinants of a specific inactive protein kinase conformation. , 2013, Chemistry & biology.

[39]  R. Kirken,et al.  Analysis of Janus tyrosine kinase phosphorylation and activation. , 2013, Methods in molecular biology.

[40]  M. Heinrich,et al.  Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia , 2012, Leukemia.

[41]  Z. Nagy,et al.  Signal Transducer and Activator of Transcription 5b (Stat5b) Serine 193 Is a Novel Cytokine-induced Phospho-regulatory Site That Is Constitutively Activated in Primary Hematopoietic Malignancies* , 2012, The Journal of Biological Chemistry.

[42]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[43]  S. Hubbard,et al.  The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling , 2011, Nature Structural &Molecular Biology.

[44]  I. Behrmann,et al.  Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. , 2011, Chemistry & biology.

[45]  K. Garcia,et al.  Structural snapshots of full-length Jak1, a transmembrane gp130/IL-6/IL-6Rα cytokine receptor complex, and the receptor-Jak1 holocomplex. , 2011, Structure.

[46]  Frédérick A. Mallette,et al.  SOCS1 links cytokine signaling to p53 and senescence. , 2009, Molecular cell.

[47]  T. Boggon,et al.  JAK3: a two-faced player in hematological disorders. , 2009, The international journal of biochemistry & cell biology.

[48]  M. Loh,et al.  JAK mutations in high-risk childhood acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.

[49]  P. Gregersen,et al.  Structural biology of shared cytokine receptors. , 2009, Annual review of immunology.

[50]  J. O’Shea,et al.  Janus kinases in immune cell signaling , 2009, Immunological reviews.

[51]  M. Loh,et al.  Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study , 2008, Leukemia.

[52]  J. Frost,et al.  Phosphorylation of Human Jak3 at Tyrosines 904 and 939 Positively Regulates Its Activity , 2008, Molecular and Cellular Biology.

[53]  P. Murray.  The JAK-STAT Signaling Pathway: Input and Output Integration1 , 2007, The Journal of Immunology.

[54]  H. Fujii.  Mechanisms of Signal Transduction from Receptors of Type I and Type II Cytokines , 2007, Journal of immunotoxicology.

[55]  Stephanie Kreis,et al.  Jaks and cytokine receptors--an intimate relationship. , 2006, Biochemical pharmacology.

[56]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[57]  W. Alexander,et al.  Suppressor of Cytokine Signaling-1 Regulates Signaling in Response to Interleukin-2 and Other γc-dependent Cytokines in Peripheral T Cells* , 2003, Journal of Biological Chemistry.

[58]  F. Uckun,et al.  Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery. , 1999, Leukemia & lymphoma.

[59]  W. Farrar,et al.  Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STAT5 recruitment by a COOH-terminal region of the IL-2 receptor beta-chain. , 1995, Cytokine.